Organiser:Informa Markets Time: September 8-10, 2024 Address:El-Nasr Rd, Al Estad, Nasr City, Cairo Governorate Exhibition hall:Cairo International Convention Centre Product range: Vitamins, Hormones, Antipyretic Analgesics, Digestive System Medications, Anti-infective Drugs, Antiparasitic Drugs, Cardiovascular System Medications, Intermediates Pharmaceutical Packaging Materials: PVC/PVDC Laminates, PVC Rigid Sheets, PS Sheets, Anti-Counterfeiting Technology for Packaging, Label Sleeve Technology, Labeling Machines, Packaging Containers, Form-Fill-Seal Machines, Wrapping Machines, Paper Film Packaging Machinery, Bag Packaging Machines, etc. Infusion Equipment Production Lines, Dryers, Water Treatment Equipment, Refrigeration Compressors, Distillation Equipment, Sterilization Equipment, Tablet Presses, Coating Machines About Pharmaconex: Pharmaceutical Ingredients & Technology Exhibition in Cairo, Egypt, is the most renowned exhibition for pharmaceutical ingredients and technology in Egypt. Hosted by the renowned British exhibition company Informa Markets, with extensive experience and strong capabilities in organizing exhibitions, Pharmaconex plays a significant role in exploring the markets of Egypt and Africa.
Early detection of cancer significantly increases the likelihood of successful treatment across various cancer types. In addition to personalized evaluation of therapy benefits and risks, continuous monitoring of treatment success is vital. Traditionally, oncologists rely on imaging technology and invasive procedures such as tissue biopsies, punctures, and endoscopic measures to monitor patients. Now, researchers have further developed an advanced method, a type of liquid biopsy that utilizes blood samples rather than direct tissue sampling for detecting various types of cancer. The technique, developed by researchers at the University of Zurich (UZH, Zurich, Switzerland) and the University Hospital Zurich (USZ, Zurich, Switzerland), involves sequencing and analyzing DNA fragments that circulate in the blood of patients to identify changes specific to particular cancers. The research team examined alterations in the number and length distribution of the DNA fragments, enabling them to distinguish between biologically less and more aggressive metastatic cancers even earlier ...
By Don Tracy, Associate Editor Kisnula is the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, company says. The FDA has approved Eli Lilly’s Kisunla (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion) to treat adults with early symptomatic Alzheimer’s disease, including mild cognitive impairment and mild dementia with confirmed amyloid pathology. According to the company, Kisunla the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, potentially reducing costs and infusion frequency. Approval was based on results from the Phase III TRAILBLAZER-ALZ 2 study.1 “Kisunla demonstrated very meaningful results for people with early symptomatic Alzheimer’s disease, who urgently need effective treatment options. We know these medicines have the greatest potential benefit when people are treated earlier in their disease, and we are working hard in partnership with others to improve detection and diagnosis,” said Anne White, EVP, president, Lilly Neuroscience, Eli ...
Eli Lilly’s Kisunla is now FDA approved for treating patients in the early stages of Alzheimer’s disease. In addition to slowing cognitive decline and disease progression, clinical trial results showed that amyloid beta plaques were reduced to the point where some patients could stop taking the infused therapy. By Frank VinluanEli Lilly Alzheimer’s disease drug has received its long-awaited FDA approval, bringing patients a treatment that works similarly to an Eisai medication for the neurodegenerative disorder but with dosing advantages that patients might prefer. The Tuesday regulatory decision comes less than a month after an FDA advisory committee voted unanimously that the benefits of the Lilly drug in slowing cognitive decline outweigh its safety risks. The approval covers the treatment of Alzheimer’s patients with mild cognitive impairment or mild dementia, the same population that was evaluated in clinical trials. Known in development as donanemab, Lilly will market its new Alzheimer’s ...
Organiser:China Association for Pharmaceutical Equipment Time:November 17-19, 2024 Address:No. 198, Huizhan Road, Siming District, Xiamen City Exhibition hall: Xiamen International Convention and Exhibition Center Product range: Raw Material Pharmaceutical Equipment & Machinery: Reaction equipment, tower equipment, crystallization equipment, separation machinery & equipment, extraction equipment, heat exchangers, evaporation equipment, distillation equipment, drying machinery & equipment, storage equipment, sterilization equipment, etc. Pharmaceutical Preparation Machinery: Granule machinery, tablet machinery, capsule machinery, powder injection machinery, small-volume injection machinery & equipment, large-volume injection machinery & equipment, pill machinery, suppository machinery, ointment machinery, oral liquid preparation machinery, aerosol machinery, ophthalmic preparation machinery, pharmaceutical film machinery, etc. Pharmaceutical Packaging Machinery & Materials: Direct packaging machinery for pharmaceuticals, outer packaging machinery for pharmaceutical packaging materials, pharmaceutical packaging material manufacturing machinery, pharmaceutical packaging materials, packaging production lines, packaging software products, integrated packaging solutions, etc. Pharmaceutical Water (Gas) Equipment: Pharmaceutical process gas (steam) equipment, purified water equipment, water for injection equipment, ...
Don Tracy, Associate Editor Reportedly, data from the IMROZ study marks the first time an anti-CD38 monoclonal antibody combined with standard-of-care therapy has demonstrated significant improvement in progression-free survival for newly diagnosed transplant-ineligible multiple myeloma. Results from the IMROZ Phase III trial show that Sanofi’s Sarclisa (isatuximab-irfc) in combination with standard-of-care therapy comprised of lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death by 40% compared to a solo VRd regimen in patients with newly diagnosed transplant-ineligible multiple myeloma (MM). According to the company, the data represents the first time an anti-CD38 monoclonal antibody combined with VRdsupported a significant improvement in progression-free survival (PFS) for these patients. “The significant progression-free survival (PFS) benefit observed with Sarclisa combination therapy compared to VRd is important and encouraging for patients with newly diagnosed multiple myeloma. Effective frontline therapy has the potential to modify the course of the disease, which ...
These notes serve not only as a means to raise capital but also as a bridge to future financing rounds or significant liquidity events. By Jaylon M. ReynoldsIn the realm of biotech and pharmaceuticals, fundraising often plays a pivotal role in driving innovation and progress. Biotech and pharmaceutical companies, whether private startups or established public firms, frequently turn to convertible notes as a strategic financial instrument. These notes serve not only as a means to raise capital but also as a bridge to future financing rounds or significant liquidity events. Convertible notes are utilized, structured, valued, and accounted for in various ways within the context of the biotech and pharmaceutical industries. Private companies For burgeoning private biotech and pharmaceutical firms, navigating the journey from research and development to commercialization can be financially demanding. Convertible notes offer a flexible financing solution, providing companies with the necessary capital to fuel their operations ...
Breast cancer represents 30% of all new cancer diagnoses in women annually, with projections from the American Cancer Society indicating that 42,500 women will succumb to the disease in 2024. Researchers have now developed a new artificial intelligence (AI) architecture capable of detecting breast cancer with a remarkable 99.72% accuracy, demonstrating the potential to redefine digital pathology. This development follows a previous initiative by the same research team at Northeastern University (Boston, MA, USA) which launched a web-based AI application aimed at diagnosing prostate cancer more efficiently and accurately. These projects are part of a broader effort to establish an online platform that allows physicians to utilize advanced AI techniques for diagnosing various cancers. For the breast cancer project, the research team utilized the publicly accessible Breast Cancer Histopathological Database, which includes images of both malignant and benign breast tissues. Leveraging this resource, they built an ensemble deep learning model ...
Don Tracy, Associate Editor As a part of National HIV Testing Day, the Centers for Disease and Control Prevention encourages testing as a part of taking charge of individual health and wellness. Today is National HIV Testing Day (NHTD) and as part of this year’s theme, “Level up your self-love: check your status,” individuals across the United States are being encouraged to get tested to show value, respect, and compassion for each other by taking charge of our health and wellness, according to the Centers for Disease and Control Prevention (CDC). “HIV testing is an essential entry point for services such as PrEP for those without HIV, and HIV treatment for those who have HIV,” reports the CDC. “Testing programs have been critical contributors to the 12% decrease in estimated HIV infections from 2018 to 2022, and a major factor contributing to ongoing disparities in HIV is a lack of ...
The Phase 3 results for ocedurenone come less than nine months after Novo Nordisk acquired the drug from KBP Biosciences. Novo Nordisk has stopped the clinical trial in uncontrolled hypertension and chronic kidney disease, but is evaluating potential applications of the small molecule in other indications. By Frank VinluanA Novo Nordisk drug for hypertension and chronic kidney disease has failed a pivotal study, a setback to the Danish pharmaceutical giant’s effort to bring patients a new therapy with potential safety and efficacy advantages over currently approved medications in the drug class, including a product marketed by Bayer. Novo Nordisk did not release specific details about the Phase 3 results for the drug, ocedurenone. The company said Wednesday that an independent data monitoring committee recommended stopping the trial after a prespecified interim analysis. Ocedurenone is a small molecule designed to block the mineralocorticoid receptor. When overactivated, this receptor can contribute to ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.